by Stephen Levin
Those venture capitalists and other investors who have been suggesting recently that the spinal device market is overheated, overcrowded, and...
Strength in Spine
Those venture capitalists and other investors who have been suggesting recently that the spinal device market is overheated, overcrowded, and basically over as a prime investment opportunity were few and far between at Windhover's "In Spine and Orthopedics" conference held in Las Vegas in December. The meeting, which is the largest strategic partnering conference for emerging spine and orthopedic companies, found investors and entrepreneurs feeling bullish about the prospects for the spinal device market, as reflected in the panel discussion excerpted here.
More from Business Strategy
• By
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
• By
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
• By
Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.
• By
Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.
More from In Vivo
• By
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
• By
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.